Composition and histone substrates of polycomb repressive group complexes change during cellular differentiation

被引:343
作者
Kuzmichev, A
Margueron, R
Vaquero, A
Preissner, TS
Scher, M
Kirmizis, A
Ougang, XS
Brockdorff, N
Abate-Shen, C
Farnham, P
Reinberg, D [1 ]
机构
[1] Howard Hughes Med Inst, Div Nucle Acids Enzymol, Dept Biochem, Piscataway, NJ 08854 USA
[2] Robert Wood Johnson Med Sch, Ctr Adv Biotechnol & Med, Dept Med, Piscataway, NJ 08854 USA
[3] Robert Wood Johnson Med Sch, Inst Canc, Piscataway, NJ 08854 USA
[4] Hammersmith Hosp, Imperial Coll, X Inactivat Grp,Clin Sci Ctr,Sch Med, MRC, London W12 0NN, England
[5] Univ Wisconsin, Sch Med, McArdle Lab Canc Res, Madison, WI 53705 USA
关键词
methylation; prostate cancer; Ezh2; histone H1;
D O I
10.1073/pnas.0409875102
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Changes in the substrate specificities of factors that irreversibly modify the histone components of chromatin are expected to have a profound effect on gene expression through epigenetics. Ezh2 is a histone-lysine methyltransferase with activity dependent on its association with other components of the Polycomb Repressive Complexes 2 and 3 (PRC2/3). Ezh2 levels are increasingly elevated during prostate cancer progression. Other PRC2/3 components also are elevated in cancer cells. Overexpression of Ezh2 in tissue culture promotes formation of a previously undescribed PRC complex, PRC4, that contains the NAD(+)-dependent histone deacetylase SirT1 and isoform 2 of the PRC component Eed. Eed2 is expressed in cancer and undifferentiated embryonic stem (ES) cells but is undetectable in normal and differentiated ES cells. The distinct PRC-s exhibit differential histone substrate specificities. These findings suggest that formation of a transformation-specific PRC complex may have a major role in resetting patterns of gene expression by regulating chromatin structure.
引用
收藏
页码:1859 / 1864
页数:6
相关论文
共 27 条
  • [1] Abate-Shen C, 2003, CANCER RES, V63, P3886
  • [2] EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer
    Adrian P. Bracken
    Diego Pasini
    Maria Capra
    Elena Prosperini
    Elena Colli
    Kristian Helin
    [J]. The EMBO Journal, 2003, 22 (20) : 5323 - 5335
  • [3] SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex
    Cao, R
    Zhang, Y
    [J]. MOLECULAR CELL, 2004, 15 (01) : 57 - 67
  • [4] Role of histone H3 lysine 27 methylation in polycomb-group silencing
    Cao, R
    Wang, LJ
    Wang, HB
    Xia, L
    Erdjument-Bromage, H
    Tempst, P
    Jones, RS
    Zhang, Y
    [J]. SCIENCE, 2002, 298 (5595) : 1039 - 1043
  • [5] Drosophila enhancer of Zeste/ESC complexes have a histone H3 methyltransferase activity that marks chromosomal polycomb sites
    Czermin, B
    Melfi, R
    McCabe, D
    Seitz, V
    Imhof, A
    Pirrotta, V
    [J]. CELL, 2002, 111 (02) : 185 - 196
  • [6] Physical and functional association of SU(VAR)3-9 and HDAC1 in Drosophila
    Czermin, B
    Schotta, G
    Hülsmann, BB
    Brehm, A
    Becker, PB
    Reuter, G
    Imhof, A
    [J]. EMBO REPORTS, 2001, 2 (10) : 915 - 919
  • [7] Point mutations in the WD40 domain of Eed block its interaction with Ezh2
    Denisenko, O
    Shnyreva, M
    Suzuki, H
    Bomsztyk, K
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 1998, 18 (10) : 5634 - 5642
  • [8] SIR2 is required for Polycomb silencing and is associated with an E(Z) histone methytransferase complex
    Furuyama, T
    Banerjee, R
    Breen, TR
    Harte, PJ
    [J]. CURRENT BIOLOGY, 2004, 14 (20) : 1812 - 1821
  • [9] Translating the histone code
    Jenuwein, T
    Allis, CD
    [J]. SCIENCE, 2001, 293 (5532) : 1074 - 1080
  • [10] Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis
    Kim, MJ
    Cardiff, RD
    Desai, N
    Banach-Petrosky, WA
    Parsons, R
    Shen, MM
    Abate-Shen, C
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (05) : 2884 - 2889